Arcutis Biotherapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARQT Nasdaq 2830 www.arcutis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcutis Biotherapeutics, Inc.

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology - Mar 10th, 2026 7:00 am
Guggenheim Raises Its Price Target on Arcutis Biotherapeutics, Inc. (ARQT) to $35 and Maintains a Buy Rating - Mar 6th, 2026 8:20 am
A Look At Arcutis Biotherapeutics (ARQT) Valuation After New ARQ 234 Trial Milestone - Mar 5th, 2026 9:07 am
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth - Mar 5th, 2026 7:00 am
Arcutis Biotherapeutics Spotlights ZORYVE Surge, 2025 Revenue Beat and Key FDA Milestones at TD Cowen - Mar 4th, 2026 6:09 am
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis - Mar 3rd, 2026 6:00 am
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference - Feb 27th, 2026 2:00 pm
Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? - Feb 27th, 2026 9:12 am
Arcutis Biotherapeutics, Inc. Q4 2025 Earnings Call Summary - Feb 26th, 2026 6:30 am
Arcutis Biotherapeutics Inc (ARQT) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... - Feb 25th, 2026 10:04 pm
Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates - Feb 25th, 2026 5:25 pm
Arcutis (ARQT) Q4 2025 Earnings Call Transcript - Feb 25th, 2026 5:08 pm
Arcutis Biotherapeutics Q4 Earnings Call Highlights - Feb 25th, 2026 4:32 pm
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Feb 25th, 2026 2:00 pm
Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments - Feb 24th, 2026 7:15 am
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Feb 19th, 2026 8:00 am
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy? - Feb 18th, 2026 8:00 am
Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards? - Feb 17th, 2026 8:05 am
Arcutis Biotherapeutics Touts ZORYVE Expansion, New Indications and 2026 Cash-Flow Breakeven Goal - Feb 11th, 2026 4:02 pm
Implied Volatility Surging for Arcutis Biotherapeutics Stock Options - Feb 10th, 2026 6:32 am